Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
INFED (iron dextran) is an intravenous iron replacement therapy indicated for treatment of iron deficiency anemia in patients who cannot tolerate or absorb oral iron. It is a small-molecule iron-carbohydrate complex that replenishes depleted iron stores and hemoglobin in the body.
Product approaching loss of exclusivity with minimal competitive pressure (30/100), suggesting limited growth trajectory and likely smaller, maintenance-focused commercial team.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women
Working on INFED offers limited career growth due to its mature, LOE-approaching status and minimal linked job openings. This role is best suited for professionals seeking stability in a maintenance-mode product or those early in their career looking for foundational pharmaceutical experience.
Worked on INFED at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo